These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 2484685)

  • 21. Tolerance and cross-tolerance between SIN-1 and nitric oxide in bovine coronary arteries.
    Kukovetz WR; Holzmann S
    J Cardiovasc Pharmacol; 1989; 14 Suppl 11():S40-6. PubMed ID: 2484698
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SIN-1 stimulates the production of cyclic GMP but not cyclic AMP in porcine aortic endothelial cells.
    Schini VB; Vanhoutte PM
    J Cardiovasc Pharmacol; 1989; 14 Suppl 11():S91-4. PubMed ID: 2484708
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mode of action of nitrates with regard to vasodilatation and tolerance.
    Kukovetz WR; Holzmann S
    Z Kardiol; 1986; 75 Suppl 3():8-11. PubMed ID: 2879392
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of the action of nitric oxide prodrugs by pyocyanin: mechanistic studies.
    Hussain AS; Bozinovski J; Maurice DH; McLaughlin BE; Marks GS; Brien JF; Nakatsu K
    Can J Physiol Pharmacol; 1997 May; 75(5):398-406. PubMed ID: 9250373
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Properties of purified soluble guanylate cyclase activated by nitric oxide and sodium nitroprusside.
    Lewicki JA; Brandwein HJ; Mittal CK; Arnold WP; Murad F
    J Cyclic Nucleotide Res; 1982; 8(1):17-25. PubMed ID: 6127356
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nitric oxide regulates the calcium current in isolated human atrial myocytes.
    Kirstein M; Rivet-Bastide M; Hatem S; Bénardeau A; Mercadier JJ; Fischmeister R
    J Clin Invest; 1995 Feb; 95(2):794-802. PubMed ID: 7860763
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Mechanism of the vasodilating effect and blood platelet- antiaggregating activity of molsidomine and SIN-1].
    Kukovetz WR; Holzmann S
    Pathol Biol (Paris); 1987 Feb; 35(2 Pt 2):260-5. PubMed ID: 3031569
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synergistic platelet antiaggregatory effects of the adenylate cyclase activator iloprost and the guanylate cyclase activating agent SIN-1 in vivo.
    Spiecker M; Darius H; Meyer J
    Thromb Res; 1993 Jun; 70(5):405-15. PubMed ID: 7690993
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prediction of the lower esophageal sphincter pressure after oral molsidomine by sydnonimine plasma concentrations.
    Stoschus B; Fernandez I; Heller J; Neubrand M; Sauerbruch T
    Hepatogastroenterology; 1999; 46(26):933-7. PubMed ID: 10370642
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relaxations to endothelium-derived relaxing factor and the metabolite of molsidomine, SIN-1, in the aorta and the hindquarters of the rat.
    Van de Voorde J; Claeys M; Leusen I
    J Cardiovasc Pharmacol; 1989; 14 Suppl 11():S55-61. PubMed ID: 2484700
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular mechanisms of nitrovasodilator bioactivation.
    Noack E; Feelisch M
    Basic Res Cardiol; 1991; 86 Suppl 2():37-50. PubMed ID: 1683227
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation between nitric oxide formation during degradation of organic nitrates and activation of guanylate cyclase.
    Feelisch M; Noack EA
    Eur J Pharmacol; 1987 Jul; 139(1):19-30. PubMed ID: 2888663
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tolerance to nitroglycerin is caused by reduced guanylate cyclase activation.
    Romanin C; Kukovetz WR
    J Mol Cell Cardiol; 1989 Jan; 21(1):41-8. PubMed ID: 2565981
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Photoactivation of the nitric oxide donor SIN-1.
    Ullrich T; Oberle S; Abate A; Schröder H
    FEBS Lett; 1997 Apr; 406(1-2):66-8. PubMed ID: 9109387
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Explanation of the discrepancy between the degree of organic nitrate decomposition, nitrite formation and guanylate cyclase stimulation.
    Feelisch M; Noack E; Schröder H
    Eur Heart J; 1988 Jan; 9 Suppl A():57-62. PubMed ID: 2900766
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship between pharmacokinetics and pharmacodynamics of molsidomine and its metabolites in humans.
    Meinertz T; Brandstätter A; Trenk D; Jähnchen E; Ostrowski J; Gärtner W
    Am Heart J; 1985 Mar; 109(3 Pt 2):644-8. PubMed ID: 3838400
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thiol-independent stimulation of soluble guanylate cyclase by NO-containing compounds.
    Niroomand F; Mülsch A; Böhme E
    Biochem Pharmacol; 1991 Jun; 41(11):1777-9. PubMed ID: 1675052
    [No Abstract]   [Full Text] [Related]  

  • 38. New approach to molsidomine active metabolites coming from the results of 2 models of experimental cardiology.
    Żorniak M; Mitręga KA; Porc M; Krzemiński TF
    Can J Physiol Pharmacol; 2017 Feb; 95(2):111-121. PubMed ID: 27918857
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical pharmacokinetics of molsidomine.
    Rosenkranz B; Winkelmann BR; Parnham MJ
    Clin Pharmacokinet; 1996 May; 30(5):372-84. PubMed ID: 8743336
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An impurity present in some samples of SIN-1 oxidizes it to nitric oxide in anaerobic solutions.
    Wang Y; Rochelle LG; Kruszyna H; Kruszyna R; Smith RP; Wilcox DE
    Toxicology; 1994 Mar; 88(1-3):165-76. PubMed ID: 8160198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.